Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Notch signaling molecule important in type 2 immunity

19.10.2005


Findings may lead to new treatments for asthma and other inflammatory-related diseases


Cross-sections of the parasitic worm Trichuris in the lumen of the mouse gut (left). Trichuris lives partially embedded in host intestinal epithelial cells. Protective T helper cells secrete molecules called cytokines that induce cells in the gut to produce mucus (right, intestinal goblet cell, stained blue). This mucus production is typical of a Th2 response. In the case of the lung, this same type of response induces mucus production that contributes to breathing difficulties typically suffered during an asthma attack. The absence of this mucus response in mice lacking Notch is consistent with a role for this pathway in controlling Th2 inflammation.



Defects in immune system cells called T helper cells may lead to diseases characterized by a faulty inflammatory response such as autoimmunity and asthma. Understanding the molecular steps involved in how T helper cells mature may help researchers develop treatments for these diseases.

Helper T cells differentiate into two different types of cells –Th1 or Th2 – which are responsible for regulating immunity to different types of pathogens. Now, researchers at the University of Pennsylvania School of Medicine have shed light on a key molecular switch in this differentiation.


Notch is a protein that is a critical regulator of the process by which stem and other multipotent cells take on a specialized function, such as a T lymphocyte or a nerve cell in organisms ranging from fruitflies to humans. Using mice in which Notch signaling could be induced to turn off in mature T cells, the researchers showed that Notch signaling is an important determinant of whether an organism can mount an effective Th2 response. The mice lacking Notch signaling were unable to mount a protective Th2 cell response against infection by the gastrointestinal parasitic worm Trichuris muris. However, the mice did mount a healthy Th1 response to an infection by the intracellular parasite Leishmania major, showing that Notch signaling is specifically required for the Th2 arm of the immune system.

These findings indicate that regulating Notch signaling may have a therapeutic role in treating diseases caused by abnormally increased Th2 responses, such as asthma, autoimmunity, and some forms of inflammatory bowel disease. Drugs that inhibit Notch signaling, called gamma secretase inhibitors, are currently in clinical trials for T-cell leukemia and Alzheimer’s disease. This study – published in today’s issue of the Journal of Experimental Medicine – suggests that these drugs may be useful in treating diseases typified by increased Th2 responses.

Senior author Warren Pear, MD, PhD, Associate Professor of Pathology and Laboratory Medicine, was one of the original discoverers of the role of Notch signaling in T-cell development. Notch activates gene transcription in the nucleus of cells, and depending on the biochemical context, it turns certain pathways on and others off. "The potential importance of our study is that it shows that Notch signaling specifically influences Th2 immunity in a live animal when challenged with a pathogen, suggesting that drugs that inhibit Notch may be useful for treating diseases associated with a pathological Th2 response, such as asthma," says Pear. He is also a member of Penn’s Abramson Family Cancer Research Institute and The Institute for Medicine and Engineering.

Helper T cells fight many types of infectious diseases and are also the cells that regulate tolerance to self and the molecules that cause the pathogenesis of such inflammatory diseases as arthritis, inflammatory bowel disease, and asthma. Antigen-presenting cells take up pathogens and migrate to the spleen or lymph nodes, where they instruct immature T cells how to differentiate into Th1 or Th2 helper T cells, killer T cells, or other types of immune system cells.

Some of the factors that signal a T cell to become Th1 or Th2 cells are well characterized, but some are not. "The role of Notch in that decision-making has been controversial," says co-author Terry Fang, a graduate student in Penn’s Immunology Program. "And this paper weighs in on this." Some studies suggest that Notch is important for the Th1 pathway, others suggest both Th1 and Th2. This study suggests that there’s a specific requirement for Notch in Th2 differentiation only.

The specificity of Notch in regulating T-cell function is highlighted in this study. "Mice lacking Notch failed to control infection with a pathogen requiring a Th2 response, demonstrating that Notch is a critical regulator of this response," adds co-author David Artis, PhD, Assistant Professor at Penn’s School of Veterinary Medicine. "The ability of these same animals to mount strong Th1 responses demonstrates the specificity of the Notch pathway in regulating this important cell type of the immune system."

The potential clinical benefit of these new findings is that gamma secretase inhibitors may so on be available for testing in the clinics. One potential side effect of these drugs is that they inhibit other pathways besides Notch. In addition, inhibiting Notch may cause side effects because this protein is used in a wide variety of cellular processes. The new mouse model described in this paper may be particularly useful for identifying the consequences of turning Notch off in different organs, an important issue for assessing potential side effects of pharmacologic Notch inhibitors.

The current work provides the rationale for determining whether manipulating Notch signaling will be useful in combating such diseases as parasitic infections, asthma, and inflammatory bowel disease. "The exciting possibility is that therapies are available," says Pear. "The challenge, however, is determining their efficacy and safety."

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>